A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic Cancer
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study will be to evaluate the toxicities as well as the efficacy of
a chemotherapy regimen involving the combination of Gemzar, Taxotere, and Xeloda (GTX) in
patients with pancreatic cancer, who have undergone complete surgical resection of their
tumor. During the screening evaluation, subjects will have a physical exam and medical
history taken by either the PI or a Co investigator. In addition, routine blood tests and
radiological exams will be performed, to determine eligibility. Following enrollment,
patients will receive 8 cycles (1 cycle = 21 days) of GTX treatment over 6 months. During
each cycle patients will receive Gemzar and Taxotere on days 4 and 11, through an IV, over
the course of approximately 2 hours, and Xeloda will be taken orally for the first 14 days of
every cycle. Patients will receive no treatment on days 15 thru 21 of each cycle. During each
cycle of treatment patients will have a physical examination, as well as routine blood work.
The first scan will be done prior to initiation of treatment, and the next will be done at
completion of chemotherapy. A short quality of life questionnaire will also be administered
prior to cycle 1 treatment, at the 3-month point, and at the completion of chemotherapy.